Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ea1fff38e27d2aa34504ab65f60e7631 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_50e76a62002c8502a3f1d2d8c813b3cd |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-761 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1135 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-76 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-01 |
filingDate |
2012-11-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3ffc247bc71b3826525cdc7261fa3af4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_89c9a28d3f2a1d187b60df04d65f16ef http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_489382308b5d9b057ea352084114003f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1df66ff83f2256ae64a1a4bd66d0831f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2f3954ffc02b7a192f15cdce409cb660 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ba3da7543d37319bbf6a4795149d185e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c0e10d5d8903c33496555b8a2573f87d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1923a8a1d29d961aad2ad1d45380bc5a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a2331b5a3b3b7310a977b02e238cbf64 |
publicationDate |
2014-05-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
KR-20140060184-A |
titleOfInvention |
Adenoviruses containing ribozyme and shRNA and compositions for treating cancer comprising the same |
abstract |
The present invention relates to adenoviruses for cancer treatment, and more particularly, to a gene construct to which a hTERT ribozyme and a therapeutic gene HSVtk (Herpes simplex virus thymidine kinase) are linked and additionally a gene construct containing an AIMP2-DX2- ≪ RTI ID = 0.0 > adenovirus < / RTI > It is expected that the composition for treating cancer containing adenovirus of the present invention exhibits a superior tumor suppressive activity than an existing anticancer agent or an adenovirus containing conventional hTERT (human telomerase reverse transcriptase) ribozyme, . |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109073638-B http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109073638-A |
priorityDate |
2012-11-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |